skip to main content
media conference

Press Releases

  • September 06, 2017

    Canadian, international researchers find new candidate drivers, subtype diversity in study of whole-genome landscape for children’s brain cancer

    A new study has analyzed hundreds of sequenced medulloblastoma (MB) samples, identifying new targets that could give children with this disease less harmful therapeutic options.

  • September 06, 2017

    Vancouver team identifies new class of molecules with potential in treating metastatic prostate cancer

    A recent study by a prolific TFRI-funded team has demonstrated that disrupting ERG transcriptional activity is sufficient to suppress the major characteristics of ERG-transformed prostate cancers.

  • September 06, 2017

    Vaccine shows promise in models, eradicates intra-abdominal tumours in over 90 per cent of mice

    Ontario cancer researchers have found that an oncolytic virus may lead to a promising new therapy option for patients with peritoneal carcinomatosis, a disseminated intra-abdominal tumour.

  • September 06, 2017

    Study finds diffuse optical spectroscopic (DOS) texture features can predict breast cancer response prior to neoadjuvant chemotherapy

    Diffuse optical spectroscopic texture features can predict breast cancer response to neoadjuvant chemotherapy in locally advanced breast cancer patients before therapy even begins.

  • September 06, 2017

    Why does relapse occur in aggressive leukemia? Canadian researchers crack the case

    A team of Canadian cancer researchers has shown that rare, therapy-resistant leukemia stem cells are already present at diagnosis in patients who experience relapses of acute myeloid leukemia (AML).

  • September 06, 2017

    TP53 polymorphisms and MDM2 SNP309 are not correlated with pre-menopausal cancer risk, study suggests

    While significant accolades are given to scientists who discover genetic mutations that are linked to cancer, it is equally important to determine factors that are not correlated.

  • September 06, 2017

    Subtype-specific alterations in BCL2 linked to poor post-treatment outcomes in non-Hodgkin lymphoma

    Subtype-specific alterations in a driver gene for non-Hodgkin lymphoma (BCL2) is strongly associated with poor patient outcomes after treatment.

  • September 06, 2017

    Discovery of seven new ovarian cancer subtypes opens door for more targeted treatments

    The discovery of seven new genetic subtypes of ovarian cancer may lead to targeted treatments for women diagnosed with this disease, including those with the most malignant form.

  • September 05, 2017

    Three 2017 PPG awards announced for cutting-edge projects in leukemia, oncolytic viruses, nanoparticle imaging

    The Terry Fox Research Institute has invested nearly $21.5-million to renew three 2017 Terry Fox New Frontiers Program Project Grants (PPGs).

  • June 30, 2017

    Canadian hero Terry Fox’s cancer research legacy lives on: VICE Sports

    Two features articles published by VICE Sports for Canada 150 are calling Terry Fox the most important athlete in Canadian history whose cancer research legacy lives on.

  • June 30, 2017

    Lung cancer screening may save both lives and money, study suggests

    New research from a TFRI-funded team suggests screening for lung cancer could save money – and lives – especially if it also identifies other tobacco-related conditions in high-risk individuals.

  • June 22, 2017

    One in two Canadians will get cancer, but research offers hope for cures

    Terry’s dream was to fund research to cure cancer, and he inspired us with that dream. We believe that it is through research that cures to cancer will be found, and survival rates for even the most challenging cancers will continue to increase.

  • May 29, 2017

    TFRI's Dr. Victor Ling recognized for breakthrough in fighting drug-resistant cancers

    Dr. Victor Ling, president and scientific director of The Terry Fox Research Institute, has been recognized by The Vancouver Sun for his breakthrough in fighting drug-resistant cancers.

  • May 24, 2017

    MATE2 expression a negative predictive biomarker to metformin’s efficacy in cancer treatment, study suggests

    The drug metformin is typically used to treat Type 2 diabetes, and some cancer patients have shown improved outcome when given the drug. A recent study by TFRI’s hypoxia group sheds new light on biomarkers that may indicate the drug’s efficacy in patients.

  • May 24, 2017

    Groundbreaking study sheds light on signaling molecules that control human hematopoietic stem cell survival and growth

    TFRI’s long-funded program project on human leukemia has made groundbreaking progress in the quest to expand human blood stem cells for therapeutic purposes.

Back to Top